FDA expands labeling for SmartLight
Israeli computerized light box developer SmartLight this month got the go-ahead from the Food and Drug Administration for expanded labeling for its products. On June 14, the FDA cleared SmartLight’s claim that, compared with conventional
Israeli computerized light box developer SmartLight this month got the go-ahead from the Food and Drug Administration for expanded labeling for its products. On June 14, the FDA cleared SmartLights claim that, compared with conventional light boxes, the companys motorized system substantially improves clinicians ability to see more detail in films. SmartLight submitted a study of more than 1000 radiologists reading quality control mammography films to back up its 510(k) filing (SCAN 5/26/99).
The FDA also cleared SmartLights claim that its viewing systems can reduce effects of age on the ability of older radiologists to see small, low-contrast objects. According to SmartLight, radiologists aged 45 to 60 viewing x-rays on its light boxes can detect smaller, lower-contrast objects than their 30-year-old colleagues can using conventional light boxes.
© 1999 Miller Freeman, Inc.All rights reserved.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
